NEW YORK, June 4 – Illumina said Monday that R. Scott Greer, chairman and CEO of Abgenix, had been elected to its board of directors.

"We are honored that Scott has agreed to join our board. He brings a solid record of leadership and accomplishment in the life sciences industry and his insight and experience will be a tremendous asset to the company," said Jay Flatley, Illumina’s CEO, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.